AI Article Synopsis
- The study focuses on patients with cardiac involvement from AL and ATTR Amyloidosis, using cardiopulmonary exercise testing (CPET) to assess their functional capacity.
- Results show that both types of Amyloidosis have significantly reduced peak VO2, with stronger correlations between cardiac biomarkers and peak VO2 in AL Amyloidosis compared to ATTR.
- The findings suggest that the observed toxicity in AL Amyloidosis may be linked to its impact on heart function, providing further evidence for the severity of this condition.
Article Abstract
Background: Cardiac involvement and dysfunction are common in patients presenting with AL and ATTR Amyloidosis. Cardiopulmonary exercise testing (CPET) performance is the gold standard to quantify functional capacity.
Patients And Methods: In this study, we evaluated CPET measurements in 41 patients with cardiac Amyloidosis and their correlation with current amyloid specific staging criteria.
Results: In both AL and ATTR cardiac Amyloidosis, percent predicted peak VO2 is significantly reduced and correlates with biomarker abnormalities. The association of cardiac biomarkers with peak VO2 is stronger for AL Amyloidosis (NT-proBNP (r = -0.57, P=0.006), Troponin (r = -0.70, p < 0.001) than ATTR (NT-proBNP (r = -0.4, P = 0.04) and Troponin (r = -0.57, P = 0.002) despite lower left ventricular mass in the former, suggesting that this may be further evidence for light chain toxicity in AL amyloidosis.
Conclusion: Our findings suggest further evidence for AL toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2021.03.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!